ABO and Rh Blood Group Systems, Inheritance, and Rh Incompatibility
Fundamentals of the ABO Blood Group System
- Discovery: The ABO blood group system was discovered by Karl Landsteiner.
- Physiological Basis: Classification is based on the presence or absence of two surface antigens, designated as A and B, located on red blood cells (RBCs), alongside corresponding antibodies present in plasma.
- Surface Antigens: Antigens are specific molecular structures or substances located directly on the outer membrane surface of RBCs.
- Plasma Antibodies: Antibodies are defensive proteins residing within the blood plasma.
- Agglutination Reaction: The reaction between a specific surface antigen and its corresponding plasma antibody (e.g., A antigen reacting with Anti-A antibody) results in agglutination, which is the clumping of RBCs.
- Clinical Transfusion Mandate: A compatibility test must always be conducted prior to performing any blood transfusion to avoid severe agglutination reactions.
Classification and Specifics of ABO Blood Groups
- Blood Group A:
- RBC Surface Antigen: A antigen.
- Plasma Antibody: Anti-B antibody.
- Blood Group B:
- RBC Surface Antigen: B antigen.
- Plasma Antibody: Anti-A antibody.
- Blood Group AB:
- RBC Surface Antigens: Both A and B antigens.
- Plasma Antibodies: None (neither Anti-A nor Anti-B antibodies are present in plasma).
- Blood Group O:
- RBC Surface Antigens: None (neither A nor B antigen is present on the RBC surface).
- Plasma Antibodies: Both Anti-A and Anti-B antibodies.
- Universal Donor Concept:
- Blood Group O (specifically O− / O-negative) is classified as the universal donor.
- Individuals with this blood group can donate blood to individuals of all other blood groups because their RBCs lack both A and B surface antigens.
- Universal Recipient Concept:
- Blood Group AB (specifically AB+ / AB-positive) is classified as the universal recipient.
- Individuals with this blood group can receive blood from individuals of all other blood groups because their plasma contains no Anti-A or Anti-B antibodies.
Genetics and Inheritance Patterns of ABO Blood Groups
- Chromosomal Location and Gene Control: The ABO blood group system is governed by a single gene designated as I (or i), located on chromosome 9.
- Hereditary Nature: Blood groups are inherited directly from parents.
- Allelic Variants:
- IA Allele: Encodes and produces the A surface antigen.
- IB Allele: Encodes and produces the B surface antigen.
- i Allele: Does not produce either A or B antigen (associated with blood group O).
- Gene Interaction and Expression Principles:
- Codominance: The alleles IA and IB are codominant with respect to each other; both express simultaneously when inherited together, resulting in the AB phenotype.
- Dominance/Recessiveness: The i allele is completely recessive to both IA and IB alleles.
- Phenotype-to-Genotype Mapping:
- Blood Group A: Genotypes IAIA (homozygous) or IAi (heterozygous).
- Blood Group B: Genotypes IBIB (homozygous) or IBi (heterozygous).
- Blood Group AB: Genotype IAIB (heterozygous codominant).
- Blood Group O: Genotype ii (homozygous recessive).
The Rh Blood Group System
- Definition and Physiological Basis: The Rh blood group system is defined by the presence or absence of another antigen known as the Rh factor (specifically designated as the D antigen) on the surface of RBCs.
- Discovery History: Discovered in 1940 by Karl Landsteiner and Alexander Wiener. The system was named after the Rhesus monkey, in which the D antigen was first studied and identified.
- Chromosomal Location: The Rh factor is controlled by a distinct, separate gene (for Rh+ and Rh−) located on chromosome 1.
- Categorization and Population Distribution:
- Rh-Positive (Rh+):
- D antigen is PRESENT on the RBC surface.
- Accounts for approximately 80–85% of the human population.
- Phenotypic examples: A+, B+, AB+, O+.
- Rh-Negative (Rh−):
- D antigen is ABSENT from the RBC surface.
- Accounts for approximately 15–20% of the human population.
- Phenotypic examples: A−, B−, AB−, O−.
Sensitization Mechanisms and Rh Transfusion Rules
- Induction of Anti-Rh Antibodies:
- Unlike the ABO blood group system, Rh− individuals do not naturally possess anti-Rh antibodies in their plasma.
- Anti-Rh antibodies are produced only after an Rh− person is exposed to Rh+ blood.
- Exposure occurs through two primary routes:
- Blood transfusion containing Rh+ blood.
- Gestation/pregnancy involving an Rh+ fetus.
- Rh Transfusion Protocols:
- Rh+→Rh+: An Rh+ recipient can safely receive Rh+ blood.
- Rh−→Rh−: An Rh− recipient should strictly receive only Rh− blood.
- Rh−←Rh+: Transfusion of Rh+ blood into an Rh− individual causes sensitization, triggering the immune system to synthesize anti-Rh antibodies.
Rh Incompatibility and Erythroblastosis Foetalis
- Definition and Nomenclature: Erythroblastosis Foetalis, also known as Haemolytic Disease of the Newborn (HDN), is a medical condition in which maternal anti-Rh antibodies cross the placental barrier and destroy the erythrocytes of an Rh+ fetus, causing severe haemolytic anaemia.
- Parental Combination Triggering Incompatibility:
- Mother: Rh-negative (Rh−).
- Father: Rh-positive (Rh+).
- Fetus: Rh-positive (Rh+).
- Mechanism during First Pregnancy:
- During normal gestation, maternal and fetal blood supplies remain separated by the placental barrier.
- At delivery (or during events such as miscarriage, abortion, physical trauma, or invasive procedures like amniocentesis), a small volume of fetal Rh+ blood may leak into the maternal bloodstream.
- The mother's immune system identifies the fetal D antigen as foreign and synthesizes anti-Rh (anti-D) antibodies, a process known as sensitization.
- First Child Outcome: The first baby is usually born normal and unaffected because maternal antibody synthesis occurs only after exposure to fetal blood late in or after delivery.
- Mechanism during Second Rh+ Pregnancy:
- The mother retains active, pre-formed anti-Rh antibodies in her bloodstream.
- These antibodies belong to the IgG class, which are small enough to readily cross the placenta.
- Maternal IgG anti-Rh antibodies pass into fetal circulation and destroy fetal Rh+ RBCs, resulting in severe haemolysis.
- Clinical Manifestations in the Fetus/Newborn:
- Haemolytic anaemia.
- Jaundice (hyperbilirubinemia resulting from excessive RBC breakdown).
- Enlarged liver and spleen (hepatosplenomegaly).
- Hydrops fetalis (generalized severe fetal oedema).
- Heart failure (in severe presentations).
- Stillbirth or early neonatal death if untreated.
Prophylactic Interventions and High-Yield Immunological Comparisons
- Prevention of Erythroblastosis Foetalis:
- Can be prevented by administering an Anti-D (Rh immunoglobulin / Anti-D Rh Ig) injection to the Rh− mother.
- Clinical Indications and Timing for Anti-D:
- Within 72hours after the delivery of an Rh+ baby.
- Following a miscarriage or abortion.
- Following an ectopic pregnancy.
- Following invasive prenatal diagnostic procedures such as amniocentesis.
- Mechanism of Action: Injected Anti-D immunoglobulin binds to and destroys fetal Rh+ RBCs circulating in the mother's blood before her immune system can recognize the antigens and undergo primary sensitization.
- High-Yield Immunological Distinctions:
- Rh Antibodies (IgG): Rh antibodies belong to the IgG class, enabling them to cross the placenta and affect the fetus.
- ABO Antibodies (IgM): ABO antibodies belong primarily to the IgM class, which are large pentameric structures that generally cannot cross the placental barrier.
- Pregnancy Vulnerability: The initial Rh+ pregnancy of an Rh− mother is unaffected, whereas subsequent Rh+ pregnancies carry a high risk of HDN if Anti-D prophylaxis is not administered.